<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243175</url>
  </required_header>
  <id_info>
    <org_study_id>2016_77</org_study_id>
    <secondary_id>2017-004371-31</secondary_id>
    <nct_id>NCT03243175</nct_id>
  </id_info>
  <brief_title>Avoiding Anticoagulation After IntraCerebral Haemorrhage</brief_title>
  <acronym>A3ICH</acronym>
  <official_title>Avoiding Anticoagulation After IntraCerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant&#xD;
      drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation&#xD;
      (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH).&#xD;
      Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular&#xD;
      non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an&#xD;
      intracerebral haemorrhage.&#xD;
&#xD;
      Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should&#xD;
      start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid&#xD;
      anticoagulation and LAAC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label randomised controlled multicentre clinical trial with masked outcome assessment&#xD;
      (PROBE design) comparing 3 strategies (1:1:1): anticoagulation with a Direct OAC (Apixaban&#xD;
      5mgx2/day) vs avoid anticoagulation with left atrial appendage closure (LAAC) compared to&#xD;
      usual care (avoid anticoagulation).&#xD;
&#xD;
      Primary outcome: the net clinical benefit (composite outcome of major ischaemic and&#xD;
      haemorrhagic events) during a follow-up of 24 months (adjudication committee masked to the&#xD;
      randomisation arm&#xD;
&#xD;
      The results of A3ICH will help the clinician to decide which strategy is the most effective&#xD;
      in terms of benefit/risk ratio to prevent the risk of stroke or systemic embolism in patients&#xD;
      with a history of ICH and AF. A3ICH will address this increasingly common dilemma and could&#xD;
      affect clinical practice.&#xD;
&#xD;
      Data from A3ICH will contribute to an international individual patient data meta-analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events</measure>
    <time_frame>within 24 months after randomization.</time_frame>
    <description>The composite endpoint will enable to evaluate the net clinical benefit of the different therapeutic strategies.&#xD;
Definition of fatal event: when death is occurring within 30 days after the events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each individual component of the composite outcome (fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events).</measure>
    <time_frame>at 12 and 24 months after randomization</time_frame>
    <description>fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>at 12 and 24 months after randomization</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>at 12 and 24 months after randomization</time_frame>
    <description>functional dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D (EuroQoL) Score</measure>
    <time_frame>at 12 and 24 months after randomization</time_frame>
    <description>health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuroradiological biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>on brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of endovascular treatment</measure>
    <time_frame>up to 30 days</time_frame>
    <description>including device related complications</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Microhaemorrhage</condition>
  <arm_group>
    <arm_group_label>Direct Oral Anticoagulant (DOAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5MG twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Left Atrial Appendage Closure (LAAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Devices will be chosen by local teams.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG</intervention_name>
    <description>Apixaban 5mg x 2 during 24 months</description>
    <arm_group_label>Direct Oral Anticoagulant (DOAC)</arm_group_label>
    <other_name>ELIQUIS 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>left atrial appendage closure</intervention_name>
    <description>left atrial appendage closure</description>
    <arm_group_label>Left Atrial Appendage Closure (LAAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Adult (older than 18 years old, no upper age limit)&#xD;
&#xD;
          -  with a history of paroxysmal, persistent or long-standing non-valvular atrial&#xD;
             fibrillation (documented on an electrocardiogram)&#xD;
&#xD;
          -  and a CHA2DS2VASc score of 2 or more who have an indication for long-term&#xD;
             anticoagulation&#xD;
&#xD;
          -  who suffered from a spontaneous intracerebral haemorrhage (while being treated with&#xD;
             oral anticoagulants or not) documented with brain CT or MRI&#xD;
&#xD;
          -  more than 14 days before randomization (no upper delay limit)&#xD;
&#xD;
          -  for whom there is a clinical equipoise regarding the choice of the best preventive&#xD;
             strategy to avoid future vascular events.&#xD;
&#xD;
        Exclusion criteria for all treatment groups&#xD;
&#xD;
          -  Pre-randomisation modified Rankin score of 4 or 5&#xD;
&#xD;
          -  Conditions other than atrial fibrillation for which the patient requires long term&#xD;
             anticoagulation (for example prosthetic mechanical heart valve)&#xD;
&#xD;
          -  Serious bleeding events within the 6 months before randomisation (except for&#xD;
             intracerebral haemorrhage)&#xD;
&#xD;
          -  Life expectancy of less than 1 year&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
        Exclusion criteria related to the LAAC only&#xD;
&#xD;
          -  Contraindications due to local, anatomical reasons (such as thrombus in the left&#xD;
             atrial appendage, infection with a risk of endocarditis)&#xD;
&#xD;
          -  Patients older than 85 years&#xD;
&#xD;
          -  CHA2DS2VASc score of 2 or 3&#xD;
&#xD;
          -  Patient or attending physician are unwilling to undergo/perform intervention for LAAC&#xD;
&#xD;
        Exclusion criteria related to the Direct OAC only&#xD;
&#xD;
          -  Chronic renal insufficiency (clearance of creatinine by Cockcroft method &lt; 30ml/min)&#xD;
&#xD;
          -  Body weight lower than 50 kg&#xD;
&#xD;
          -  Allergy to apixaban&#xD;
&#xD;
          -  Coexisting conditions predisposing to head trauma (e.g. gait disturbances,&#xD;
             uncontrolled seizures disorders)&#xD;
&#xD;
          -  Patient or attending physician are unwilling to use of Direct OAC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Cordonnier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Lille, Inserm, Univ Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Cordonnier, MD, PhD</last_name>
    <phone>3 20 44 68 14</phone>
    <phone_ext>+33</phone_ext>
    <email>charlotte.cordonnier@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charlottea Cordonnier, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHICL</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marta PASQUINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH De Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric DUMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>microhemorrhage</keyword>
  <keyword>oral anticoagulation</keyword>
  <keyword>left atrial appendage closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Prof Cordonnier (chief investigator of A3ICH) is a member of the international Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH - coordination Prof Rustam Al-Shahi Salman, UK) working towards a pre-planned individual patient data meta-analysis</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

